Pilot Testing a Novel Treatment for Inflammatory Bowel Disease by Olendzki, Barbara C. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Center for Clinical and Translational 
Science Research Retreat 
2011 UMass Center for Clinical and 
Translational Science Research Retreat 
May 20th, 5:00 PM - 7:00 PM 
Pilot Testing a Novel Treatment for Inflammatory Bowel Disease 
Barbara C. Olendzki 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat 
 Part of the Dietetics and Clinical Nutrition Commons, Digestive System Diseases Commons, 
Gastroenterology Commons, and the Translational Medical Research Commons 
Olendzki BC, Persuitte G, Silverstein T, Baldwin K, Cave D, Zawacki JK, Bhattacharya K, Ma Y. (2011). Pilot 
Testing a Novel Treatment for Inflammatory Bowel Disease. UMass Center for Clinical and Translational 
Science Research Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2011/posters/
15 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for 
Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
  Pilot Testing a Novel Treatment for Inflammatory Bowel Disease 
 
Barbara Olendzki , RD, MPH; Gioia Persuitte, MPA; Taryn Silverstein, DO;  
Katherine Baldwin, MD, David Cave, MD, PhD; John Zawacki, MD; Kanishka Bhattacharya, MD, Yunsheng Ma, MD, PhD 
 
University of Massachusetts (UMass) Medical School and UMass Memorial Health Care, Worcester, MA 
                                                                                                                  BACKGROUND and OBJECTIVE 
 
Inflammatory Bowel Disease (IBD), which includes Crohn’s disease (CD) and ulcerative 
colitis (UC), are chronic non specific inflammatory conditions.  Standard IBD treatment 
typically employs a combination of anti-inflammatory and immune suppressive 
medications; however, the pharmacological approach is not by itself curative. The Anti-
Inflammatory Diet for IBD (IBD-AID), which is derived and augmented from The Specific 
Carbohydrate Diet (SCD), is a nutritional regimen that restricts the intake of complex 
carbohydrates such as refined sugar, gluten-based grains, and certain starches from the 
diet.  These carbohydrates are thought to provide a substrate for pro-inflammatory 
bacteria.  The second component of the diet involves the ingestion of pre- and probiotics to 
help restore an anti inflammatory environment. 
  
Study Objective 
To assess the efficacy and feasibility of the Anti –Inflammatory Diet (IBD-AID) intervention 
for the treatment of IBD. 
 
METHODS 
RESULTS 
Conclusion 
  
 
 
 
 
This case series indicates the potential for the IBD-AID to be used as an adjunctive or alternative therapy for the treatment of 
IBD. Notably, 9 out of 11 patients were able to be managed without anti-TNF therapy, and 100% of the patients had their symptoms 
reduced.  To make clear recommendations for its use in clinical practice, randomized trials are needed alongside strategies to 
improve acceptability and compliance with the IBD-AID.  
 
 
 
Intervention:  Patients were recruited from the UMMHC gastroenterology clinic upon referral from 
their gastroenterologist.  They received individual instruction of the diet and its restrictions through 
5 individual nutrition sessions over approximately a 6-10 month period. Support materials were 
provided. Cooking classes were also available to the patients. 
 
Outcome Survey Measures: 
 
Ulcerative Colitis: Modified Truelove and Witts Severity Index (MTLW) 
Scoring system of 0-21 points, clinical response is defined as a decrease from baseline score of 
50% or greater, or less than 10 on 2 consecutive days 
•Number of stools/day 
•Nocturnal stools 
•Visible blood in stools 
•Fecal incontinence 
•Abdominal pain/cramping 
•General well-being 
•Abdominal tenderness 
•Use of anti-diarrheal drugs 
 
Crohn’s Disease:  Harvey Bradshaw Index (HBI) 
•General well-being (0 = very well, 1 = slightly below average, 2 = poor, 3 = very poor, 4 = terrible) 
• Abdominal pain (0 = none, 1 = mild, 2 = moderate, 3 = severe) number of liquid stools per day  
•Abdominal mass (0 = none, 1 = dubious, 2 = definite, 3 = tender)  
•Complications, with one point for each. 
 
 
  Age Sex Disease Disease duration Extent disease Dx Based on 
39 F CD 8 years Rectum to transverse colon Colonoscopy 
47 F CD 4 years Distal ileum  Colonoscopy & MRI 
39 F CD 9 years Distal ileum  Small bowel follow through 
24 F CD 14 years Small bowel  Capsule endoscopy, sigmoidoscopy 
39 M CD 7 years Ileocecal, perianal area  Colonoscopy and capsule endoscopy 
69 M UC 24 years Descending colon & rectum  Colonoscopy  
19 F UC 5 years Pan-colonic Colonoscopy 
40 M CD 1 year Colonic  Colonoscopy & MRI 
41 M CD 8 years Distal ileum  CT scan & colonoscopy  
37 F CD 4 years Ileocecal  CT scan & pathology from surgery  
70 F UC  19 years Pan-colonic Colonoscopy & histology 
Age Sex Disease Prior Tx Include Recent Tx HBI/MTLW before  HBI/MTLW after 
39 F CD ASA, IM, aTNF ASA +IBD-AID HBI       12  3 
47 F CD S, IM, aTNF S(taper) + IBD-AID HBI       9  2 
39 F CD S,IM IM + IBD-AID HBI       12 2 
24 F CD S,ASA, IM, aTNF S(taper), IM + IBD-AID HBI       15 0 
39 M CD IM, aTNF IBD+AID HBI       20  0 
69 M UC ASA, IM, aTNF  ASA, IM + IBD-AID MTLW  n/d 2; “improved”  
19 F UC S,ASA, IM, aTNF ASA, IBD-AID MTLW    6 0 
40 M CD S,ASA, IM IM + IBD-AID HBI       15 2 
41 M CD ASA, IM IM + IBD-AID HBI        4 2 
37 F CD S,ASA, aTNF; elemental diet aTNF + IBD-AID HBI        1 1; histologic remission 
70 F UC  ASA, IM, aTNF aTNF + IBD-AID MTLW    8  0 
Probiotic 
Foods 
 
Aged cheeses 
Dark 
chocolate 
Fermented 
cabbage 
Kefir 
Miso soup 
Microalgae  
Pickles 
Yogurt 
(active) 
Prebiotic 
Foods  
 
Artichokes 
Asparagus  
Bananas 
Chicory root 
Garlic 
Honey 
Leeks 
Oats 
Onions 
 
Therapy Legend:  S=steroid dependant, ASA= 5-ASA derivatives, IM=immunomodulator, aTNF=Anti-tumor necrosis factor antibody  
